1. Home
  2. CSWC vs IOVA Comparison

CSWC vs IOVA Comparison

Compare CSWC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSWC
  • IOVA
  • Stock Information
  • Founded
  • CSWC 1961
  • IOVA 2007
  • Country
  • CSWC United States
  • IOVA United States
  • Employees
  • CSWC N/A
  • IOVA N/A
  • Industry
  • CSWC Textiles
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CSWC Consumer Discretionary
  • IOVA Health Care
  • Exchange
  • CSWC Nasdaq
  • IOVA Nasdaq
  • Market Cap
  • CSWC 1.1B
  • IOVA 975.1M
  • IPO Year
  • CSWC N/A
  • IOVA N/A
  • Fundamental
  • Price
  • CSWC $20.20
  • IOVA $1.95
  • Analyst Decision
  • CSWC Buy
  • IOVA Buy
  • Analyst Count
  • CSWC 5
  • IOVA 11
  • Target Price
  • CSWC $23.50
  • IOVA $10.80
  • AVG Volume (30 Days)
  • CSWC 637.7K
  • IOVA 12.5M
  • Earning Date
  • CSWC 11-03-2025
  • IOVA 11-06-2025
  • Dividend Yield
  • CSWC 12.50%
  • IOVA N/A
  • EPS Growth
  • CSWC N/A
  • IOVA N/A
  • EPS
  • CSWC 1.64
  • IOVA N/A
  • Revenue
  • CSWC $209,032,000.00
  • IOVA $241,525,000.00
  • Revenue This Year
  • CSWC $14.60
  • IOVA $68.14
  • Revenue Next Year
  • CSWC $10.75
  • IOVA $56.64
  • P/E Ratio
  • CSWC $12.45
  • IOVA N/A
  • Revenue Growth
  • CSWC 10.52
  • IOVA 636.99
  • 52 Week Low
  • CSWC $17.46
  • IOVA $1.64
  • 52 Week High
  • CSWC $25.53
  • IOVA $12.51
  • Technical
  • Relative Strength Index (RSI)
  • CSWC 40.16
  • IOVA 39.33
  • Support Level
  • CSWC $20.31
  • IOVA $2.10
  • Resistance Level
  • CSWC $21.00
  • IOVA $2.35
  • Average True Range (ATR)
  • CSWC 0.35
  • IOVA 0.12
  • MACD
  • CSWC 0.09
  • IOVA -0.02
  • Stochastic Oscillator
  • CSWC 59.64
  • IOVA 3.26

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: